Melanoma Vaccine Reaches Phase 3 Milestone: Travel Access May Be Years Away Outside the US

Melanoma vaccine travel access is years away for most patients outside the US. Moderna and Merck’s personalized mRNA cancer vaccine Intismeran passed its first Phase 3 trial, with US approval projected as early as 2027 — but individualized manufacturing will limit global access. What medical